BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6366130)

  • 1. High-dose cytosine arabinoside in non-Hodgkin's lymphoma.
    Kantarjian H; Barlogie B; Plunkett W; Velasquez W; McLaughlin P; Riggs S; Cabanillas F
    J Clin Oncol; 1983 Nov; 1(11):689-94. PubMed ID: 6366130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose cytosine arabinoside in relapsed and refractory non-Hodgkin's lymphoma. Limited role as a single agent.
    Soiffer RJ; Caligiuri MA; Tondini C; Canellos GP
    Cancer; 1989 Nov; 64(10):2014-8. PubMed ID: 2553238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose cytosine arabinoside. Active agent in treatment of non-Hodgkin's lymphoma.
    Shipp MA; Takvorian RC; Canellos GP
    Am J Med; 1984 Nov; 77(5):845-50. PubMed ID: 6496539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin's lymphoma.
    Schilsky RL; Williams SF; Ultmann JE; Watson S
    J Clin Oncol; 1987 Mar; 5(3):419-25. PubMed ID: 3819808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
    Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
    Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin's lymphoma: a study of the French Society of Pediatric Oncology.
    Gentet JC; Patte C; Quintana E; Bergeron C; Rubie H; Pein F; Demaille MC; Philip T; Raybaud C
    J Clin Oncol; 1990 Apr; 8(4):661-5. PubMed ID: 2313335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose cytosine arabinoside in multiple myeloma.
    Kantarjian H; Dreicer R; Barlogie B; Plunkett W; Alexanian R
    Eur J Cancer Clin Oncol; 1984 Feb; 20(2):227-31. PubMed ID: 6538488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relation between plasma Ara-C and intracellular Ara-CTP levels by intermediate dose and high dose Ara-C administration in the treatment of AML].
    Yoshida T; Kobayashi K; Nakamura S; Ohtake S; Itoh K; Kanno M; Hirai J; Yasushi ; Matsuda TT
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 1):625-30. PubMed ID: 3162669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis.
    Iacoboni SJ; Plunkett W; Kantarjian HM; Estey E; Keating MJ; McCredie KB; Freireich EJ
    J Clin Oncol; 1986 Jul; 4(7):1079-88. PubMed ID: 3459811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
    Snyder MJ; Johnson DB; Daly MB; Giguere JK; Harman GH; Harden EA; Johnson RA; Leff RS; Mercier RJ; Messerschmidt GL
    Bone Marrow Transplant; 1994 Oct; 14(4):595-600. PubMed ID: 7858534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermediate-dose cytosine arabinoside in the treatment of recurrent or refractory non-Hodgkin's lymphoma.
    Takagi T; Sakai C; Oguro M
    Jpn J Clin Oncol; 1989 Jun; 19(2):123-6. PubMed ID: 2733165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma.
    Petersen FB; Appelbaum FR; Bigelow CL; Buckner CD; Clift RA; Sanders JE; Storb R; Sullivan KM; Weiden PL; Fefer A
    Bone Marrow Transplant; 1989 Sep; 4(5):483-8. PubMed ID: 2676043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
    Morra E; Lazzarino M; Inverardi D; Brusamolino E; Orlandi E; Canevari A; Pagnucco G; Bernasconi C
    J Clin Oncol; 1986 Aug; 4(8):1207-11. PubMed ID: 3461134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a combination of idarubicin, etoposide and intermediate-dose cytosine arabinoside as salvage therapy in relapsing or resistant unfavorable lymphoma.
    Brusamolino E; Passamonti F; Pagnucco G; Castagnola C; Lazzarino M; Bernasconi C
    Haematologica; 1998 Apr; 83(4):323-8. PubMed ID: 9592982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
    Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
    Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival following radiotherapy and cytarabine chemotherapy for sporadic primary central nervous system lymphoma.
    Pöttgen C; Stuschke M; Stüben G; Schmitz A; Schwechheimer K; Wacker HH; Rauhut F; Kleuker S; Wilhelm H; Grehl S; Fehlings T
    Strahlenther Onkol; 2003 Sep; 179(9):626-32. PubMed ID: 14628129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid.
    Slevin ML; Piall EM; Aherne GW; Harvey VJ; Johnston A; Lister TA
    J Clin Oncol; 1983 Sep; 1(9):546-51. PubMed ID: 6583325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma.
    Machover D; Delmas-Marsalet B; Misra SC; Ulusakarya A; Gumus Y; Frénoy N; Guettier C; Saffroy R; Innominato P; Almohamad W; Brahimi N; Haydar M; Goldschmidt E
    Biomed Pharmacother; 2010 Feb; 64(2):83-7. PubMed ID: 20044233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.